Physician profile
Michael Grassia
NPI 1235128133
$1,186.97
in general payments reported to CMS, 2019-2025
12 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $97.99 · 2021: $15.73 · 2022: $11.69 · 2023: $166 · 2024: $348 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.93 |
| Education | $113.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $319.48 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $232.32 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $188.58 | 2019-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $119.23 | 2019-2023 | Velphoro |
| Vifor Pharma, INC. | $110.17 | 2019-2024 | Veltassa |
| Mallinckrodt Enterprises LLC | $55.60 | 2019 | |
| Travere Therapeutics, INC. | $40.68 | 2024-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $32.89 | 2024 | |
| Ardelyx, INC. | $30.24 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $26.40 | 2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $19.69 | 2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grassia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.